DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
Diabetes Drug, Metformin, Suggested as ‘Breakthrough’ Treatment for Sickle Cell Anemia
Metformin, a common drug for Type 2 diabetes, could be used to “turn on” fetal hemoglobin levels in sickle cell anemia patients, according to a study by researchers at Baylor College of Medicine and Texas Children’s Cancer and Hematology Centers. The study’s lead investigator called the finding a “major breakthrough” in treating the disease.
Sickle cell patients’ adult hemoglobin causes their red blood cells to become sickle-shaped and get stuck inside the blood vessels, leading to pain and other complications. Fetal hemoglobin, a type of hemoglobin present in newborns, does not cause red blood cells to become sickle-shaped, but its production stops at about 6 months old.
Related Content
-
news & eventsBig Jump in Success for Sickle Cell TransplantsDoubling the dose of total-body irradiat...
-
news & eventsThe Upside of Bad GenesFor the last two decades, they’ve had ...
-
education & researchHome Care for Children with Sickle Cell DiseaseSickle cell disease is an inherited diso...
-
education & researchSickle cell disease: Challenges and progressDespite a long history of knowing the ge...
-
news & events
-
news & eventsLong-term opioids may not be best pain management option for all sickle cell patientsSmall study shows some on opioids report...
-
news & eventsLa Jolla Pharmaceutical company announces initiation of pivotal clinical study of LJPC-401 in patients with beta tha...La Jolla Pharmaceutical company today an...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.